Pulmonary hypertension risk factors: Difference between revisions

	Pulmonary Hypertension Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pulmonary hypertension from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pulmonary hypertension risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Google Images
American Roentgen Ray Society Images of Pulmonary hypertension risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pulmonary hypertension risk factors
CDC on Pulmonary hypertension risk factors
Pulmonary hypertension risk factors in the news
Blogs on Pulmonary hypertension risk factors
Directions to Hospitals Treating Pulmonary hypertension
Risk calculators and risk factors for Pulmonary hypertension risk factors

VisualWikitext

Latest revision as of 17:20, 9 June 2021

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor(s)-in-Chief: Ralph Matar; Rim Halaby, M.D. [2]

Overview

Pulmonary hypertension (PH) is a multifactorial disease involving genetic and environmental risk factors. Risk factors for pulmonary arterial hypertension include BMPR2 mutation, connective tissue disease, HIV infection, portal hypertension, fenfluramine use, and congenital heart disease with a shunt. Left heart and lung diseases are risk factors for PH. Patients with a hypercoagulable state (such as the presence of lupus anticoagulant, deficiency of protein C, protein S, or antithrombin III, chronic inflammatory disorders, myeloproliferative syndromes, and splenectomy) are at an increased risk for chronic thromboembolic pulmonary hypertension.

Risk Factors

Risk factors of pulmonary hypertension are divided as follows:^[1]

Pulmonary Arterial Hypertension

Shown below is a table summarizing the list of drugs associated with PAH:

Definite risk	Possible risk	Likely risk	Unlikely risk
Aminorex Fenfluramine Dexfenfluramine Toxic rapeseed oil Benfluorex	Cocaine Phenylpropanolamine St John's wort Chemotherapy Selective serotonin reuptake inhibitors Pergolide	Amphetamine L-tryptophan Methamphetamine	Oral contraceptive Estrogen therapy Smoking

Pulmonary hypertension due to Left Heart Disease

Pulmonary Hypertension due to Lung Diseases and/or Hypoxia

Alveolar hypoventilation disorders
Chronic exposure to high altitude
Chronic obstructive pulmonary disease
Developmental abnormalities
Interstitial lung disease
Pulmonary diseases with mixed restrictive and obstructive pattern
Sleep related breathing problems

Chronic Thromboembolic Pulmonary Hypertension

Pulmonary embolism
Hypercoagulability (lupus anticoagulant, deficiency of protein C, protein S, or antithrombin III, chronic inflammatory disorders, myeloproliferative syndromes, and splenectomy)

PH with Unclear and/or Multifactorial Mechanisms

References

↑ McLaughlin, VV.; Archer, SL.; Badesch, DB.; Barst, RJ.; Farber, HW.; Lindner, JR.; Mathier, MA.; McGoon, MD.; Park, MH. (2009). "ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association". Circulation. 119 (16): 2250–94. doi:10.1161/CIRCULATIONAHA.109.192230. PMID 19332472. Unknown parameter |month= ignored (help)

Template:WikiDoc Sources

[McLaughlin-2009-1] McLaughlin, VV.; Archer, SL.; Badesch, DB.; Barst, RJ.; Farber, HW.; Lindner, JR.; Mathier, MA.; McGoon, MD.; Park, MH. (2009). "ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association". Circulation. 119 (16): 2250–94. doi:10.1161/CIRCULATIONAHA.109.192230. PMID 19332472. Unknown parameter |month= ignored (help)

[1]

@@ Line 1: / Line 1: @@
-Patient ar risk of developing Pulmonary Hypertension are:
+__NOTOC__
-*Those who havefamily history of the condition.
+{{Pulmonary hypertension}}
-*Those who have certain diseases or conditions, such as heart and lung diseases, liver disease, HIV infection.
+{{CMG}}; '''Assistant Editor(s)-in-Chief:''' [[User:Ralph Matar|Ralph Matar]]; {{Rim}}
-*Those who are prone to have recurrent Pulmonary Embolism.
-*Those who use street drugs (such as cocaine) or certain diet medicines.
+==Overview==
-*Those who live at high altitudes(hypoxemia).
+Pulmonary hypertension (PH) is a multifactorial disease involving genetic and environmental risk factors. Risk factors for pulmonary arterial hypertension include [[BMPR2]] [[mutation]], [[connective tissue disease]], [[HIV infection]], [[portal hypertension]], [[fenfluramine]] use, and [[congenital heart disease]] with a [[shunt]]. [[Left heart]] and [[lung]] diseases are risk factors for PH. Patients with a [[hypercoagulable state]] (such as the presence of [[lupus anticoagulant]], deficiency of [[protein C]], [[protein S]], or [[antithrombin III]], [[inflammation#Chronic inflammation|chronic inflammatory disorders]], [[myeloproliferative syndrome]]s, and [[splenectomy]]) are at an increased risk for chronic [[thromboembolic]] pulmonary hypertension.
+==Risk Factors==
+Risk factors of pulmonary hypertension are divided as follows:<ref name="McLaughlin-2009">{{Cite journal  | last1 = McLaughlin | first1 = VV. | last2 = Archer | first2 = SL. | last3 = Badesch | first3 = DB. | last4 = Barst | first4 = RJ. | last5 = Farber | first5 = HW. | last6 = Lindner | first6 = JR. | last7 = Mathier | first7 = MA. | last8 = McGoon | first8 = MD. | last9 = Park | first9 = MH. | title = ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. | journal = Circulation | volume = 119 | issue = 16 | pages = 2250-94 | month = Apr | year = 2009 | doi = 10.1161/CIRCULATIONAHA.109.192230 | PMID = 19332472 }}</ref>
+===Pulmonary Arterial Hypertension===
+* [[BMPR2]] gene mutation
+* [[ALK1]] gene mutation
+* [[Connective tissue disease]]
+* [[HIV]] infection
+* [[Portal hypertension]]
+* [[Congenital heart disease]]
+* [[Schistosomiasis]]
+* Chronic [[hemolytic anemia]]
+* [[Drug]]s and [[toxin]]s
+Shown below is a table summarizing the list of drugs associated with PAH:
+{| style="cellpadding=0; cellspacing= 0; width: 600px;"
+|-
+| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Definite risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Possible risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Likely risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Unlikely risk
+|-
+| style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |
+* [[Aminorex]]
+* [[Fenfluramine]]
+* [[Dexfenfluramine]]
+* Toxic rapeseed oil
+* [[Benfluorex]]
+| style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |
+* [[Cocaine]]
+* [[Phenylpropanolamine]]
+* [[St John's wort]]
+* [[Chemotherapy]]
+* [[Selective serotonin reuptake inhibitor]]s
+* [[Pergolide]]
+| style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |
+* [[Amphetamine]]
+* [[L-tryptophan]]
+* [[Methamphetamine]]
+| style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |
+* [[Oral contraceptive]]
+* [[Estrogen|Estrogen therapy]]
+* [[Smoking]]
+|}
+===Pulmonary hypertension due to Left Heart Disease===
+* [[Systolic dysfunction]]
+* [[Diastolic dysfunction]]
+* Left [[valvular disease]]
+===Pulmonary Hypertension due to Lung Diseases and/or Hypoxia===
+* Alveolar [[hypoventilation]] disorders
+* Chronic exposure to high altitude
+* [[Chronic obstructive pulmonary disease]]
+* Developmental abnormalities
+* [[Interstitial lung disease]]
+* Pulmonary diseases with mixed restrictive and obstructive pattern
+* Sleep related breathing problems
+===Chronic Thromboembolic Pulmonary Hypertension===
+* [[Pulmonary embolism]]
+* [[Hypercoagulability]] ([[lupus anticoagulant]], deficiency of [[protein C]], [[protein S]], or [[antithrombin III]], [[inflammation|chronic inflammatory disorder]]s, [[myeloproliferative syndrome]]s, and [[splenectomy]])
+===PH with Unclear and/or Multifactorial Mechanisms===
+* [[Myeloproliferative disease]]
+* [[Splenectomy]]
+* [[Sarcoidosis]]
+* [[Histiocytosis]]
+* [[Lymphangioleiomyomatosis]]
+* [[Neurofibromatosis]]
+* [[Vasculitis]]
+* [[Glycogen storage disease]]
+* [[Gaucher disease]]
+* [[Thyroid]] disorder
+* Obstruction by [[tumor]]
+* Fibrosing [[mediastinitis]]
+* [[Chronic renal failure]] on [[dialysis]]
+==References==
+{{Reflist|2}}
+{{WikiDoc Help Menu}}
+{{WikiDoc Sources}}
+[[Category:Medicine]]
+[[Category:Cardiology]]
+[[Category:Pulmonology]]
+[[Category:Emergency medicine]]
+[[Category:Up-To-Date]]